Fall sounds about right. At least for the Rx division. We are just waiting for positive Nemo results to come back to get a higher price.
Compared to traditional pharma, we suck, compared to biotech we suck, compared to other medical devices we suck. Who would be so dumb and buy us???
That’s a really good question. One of my first guesses would’ve been a company that spans everything from Rare Disease to GI and could use a “Cash” drug- A & C specifically - I thought Shire. But with Takeda trying to buy Shire- that knocks them off. However, what about Novartis? And before you scoff, they have legit Pharma, big share in generics, and with their hq in Switzerland - I am sure there are relationships between the board of directors at Nestle & Novartis along with ties at Senior Leadership.
That is a really good point. J&J would take over all Inside Marketing and Finance Jobs. The sales force would be locked in place so that would be an easy transition. Would Nestle move ProActiv to the open building space in Fort Worth?
Wait, you WANT to be bought? All I can say is be careful what you wish for. I came here after an acquisition. Every single one of former coworkers are gone.
The company is losing employees left and right because of empty pipelines, poor sales, unclear and allowing competitors to overtake us in technology, and lack of marketing. Aesthetic is dying.
Home office is a shell of what it once was. Cutting back on everything and working with bare minimum to show buyer that they’re getting a leaner yet still money making acquisition.
I’m always interested in these threads until I see stupid stuff like “Aesthetics is Dying” That could not be further from the truth, so the thread just makes no sense.
